However, the genomic and proteomic revolution should make it possible to find such targets, especially because (as success with anti-VEGF/VEGFR drugs has shown) differences between tumour and normal blood vessels need not be absolute for therapy to be effective. This evidence concerns the gene KDR and neoplasm.